Evidence map›Paper›PMID 31864312›Full record

ReviewMolecular medicine (Cambridge, Mass.)2019

The neuroprotective mechanisms of ginkgolides and bilobalide in cerebral ischemic injury: a literature review.

Zili Feng, Qian Sun, Wang Chen, Yu Bai, Daihua Hu, Xin Xie

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular medicine (Cambridge, Mass.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
21.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Experimental and therapeutic medicine · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zili FengSchool of Bioscience and Engineering, Shaanxi University of Technology, No.1 Donghuan 1st Road, Hanzhong, 732001, People's Republic of China. fengzili@snut.edu.cn.ORCID 0000-0001-8455-9095
Qian SunSchool of Bioscience and Engineering, Shaanxi University of Technology, No.1 Donghuan 1st Road, Hanzhong, 732001, People's Republic of China.
Wang ChenSchool of Bioscience and Engineering, Shaanxi University of Technology, No.1 Donghuan 1st Road, Hanzhong, 732001, People's Republic of China.
Yu BaiSchool of Bioscience and Engineering, Shaanxi University of Technology, No.1 Donghuan 1st Road, Hanzhong, 732001, People's Republic of China.
Daihua HuSchool of Bioscience and Engineering, Shaanxi University of Technology, No.1 Donghuan 1st Road, Hanzhong, 732001, People's Republic of China.
Xin XieKey Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Science, Northwest University, Xi'an, 710069, People's Republic of China.
Shaanxi University of Technology · CNMinistry of Education of the People's Republic of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence and mortality of strokes have increased over the past three decades in China. Ischemic strokes can cause a sequence of detrimental events in patients, including increased permeability and dysfunction of the blood-brain barrier, brain edema, metabolic disturbance, endoplasmic reticulum stress, autophagy, oxidative stress, inflammation, neuron death and apoptosis, and cognitive impairment. Thrombolysis using recombinant tissue plasminogen activator (rtPA) and mechanical embolectomy with a retrievable stent are two recognized strategies to achieve reperfusion after a stroke. Nevertheless, rtPA has a narrow therapeutic timeframe, and mechanical embolectomy has limited rates of good neurological outcomes. EGb761 is a standardized and extensively studied extract of Ginkgo biloba leaves. The ginkgolides and bilobalide that constitute a critical part of EGb761 have demonstrated protective properties towards cerebral injury. Ginkgolides include Ginkgolide A (GA), Ginkgolide B (GB), Ginkgolide C (GC), Ginkgolide J (GJ), Ginkgolide K (GK), Ginkgolide L (GL), and Ginkgolide M (GM). This review seeks to elucidate the neuroprotective effects and mechanisms of ginkgolides, especially GA and GB, and bilobalide in cerebral injury following ischemic strokes.

Indexed as

BilobalidesBrain IschemiaGinkgolidesNeuroprotective AgentsPhytochemicalsAnimalsGinkgo bilobaHumansMicePlant ExtractsRatsBilobalidesGinkgolidesNeuroprotective AgentsPhytochemicalsPlant ExtractsBilobalideCerebral injuryGinkgolidesIschemic strokeNeuroprotective effect

Identifiers

PMID31864312
PMCPMC6925848
OpenAlexW2995711335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.